TriAct Therapeutics Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 25


  • Latest Deal Type
  • Later Stage VC

TriAct Therapeutics General Information


Developer of a novel signaling pathway inhibitor intended to meet the significant and unmet needs of lung cancer patients. The company's inhibitor focuses on high-value non-small cell lung cancer indications that effectively deny tumor cells, enabling healthcare providers to enhance the anti-tumor effects of both standard and next-generation cancer therapies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Technology Systems
Corporate Office
  • 2717 Baker Street
  • San Francisco, CA 94123
  • United States
+1 (415) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TriAct Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 01-Jan-2017 Completed Generating Revenue
1. Later Stage VC 01-Jan-2016 Completed Generating Revenue
To view TriAct Therapeutics’s complete valuation and funding history, request access »

TriAct Therapeutics Patents

TriAct Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200297644-A1 Iniparib formulations and uses thereof Active 29-Sep-2017 0000000000
EP-3687501-A1 Iniparib formulations and uses thereof Pending 29-Sep-2017 00000000
US-11628144-B2 Iniparib formulations and uses thereof Active 29-Sep-2017 00000000 000
EP-3687501-A4 Iniparib formulations and uses thereof Pending 29-Sep-2017 0000000000 0
EP-3654958-A1 Methods of patient selection and treating trxr- or prdx-overexpressed cancers Pending 22-Jun-2017 A61K31/166
To view TriAct Therapeutics’s complete patent history, request access »

TriAct Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Thomas White Co-Founder, Chief Executive Officer & President
John Schembri Chief Financial Officer
You’re viewing 2 of 3 executive team members. Get the full list »

TriAct Therapeutics Board Members (1)

Name Representing Role Since
G. Kirk Raab Self Chairman 000 0000
To view TriAct Therapeutics’s complete board members history, request access »

TriAct Therapeutics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TriAct Therapeutics FAQs

  • When was TriAct Therapeutics founded?

    TriAct Therapeutics was founded in 2008.

  • Who is the founder of TriAct Therapeutics?

    Thomas White and Jack Youngren Ph.D are the founders of TriAct Therapeutics.

  • Where is TriAct Therapeutics headquartered?

    TriAct Therapeutics is headquartered in San Francisco, CA.

  • What is the size of TriAct Therapeutics?

    TriAct Therapeutics has 25 total employees.

  • What industry is TriAct Therapeutics in?

    TriAct Therapeutics’s primary industry is Therapeutic Devices.

  • Is TriAct Therapeutics a private or public company?

    TriAct Therapeutics is a Private company.

  • What is TriAct Therapeutics’s current revenue?

    The current revenue for TriAct Therapeutics is 000000.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »